BMI is working with a network of collaborators and partners to develop and commercialize their pipeline of innovative vaccines directed against specific human pathogens through the application of their epitope-protection and other key technologies.
Download our recent publication in PLOS ONE describing the inactivation of polio using gamma irradiation: Click here.
ultraIPV™ is an inactivated polio vaccine, based on Sabin strains, which introduces a number of key advantages over current polio vaccine options. BMI’s novel non-chemical, UV-light mediated inactivation process will lead to a lower cost IPV and promises to maintain eradication, but with greater global safety and biosecurity compared with existing vaccines.
Let's Connect